Cognizant CTSH Health Sciences — Foreign currency translation adjustments
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cognizant in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The official record: Cognizant’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cognizant's health sciences — foreign currency translation adjustments.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cognizant's health sciences — foreign currency translation adjustments?
- Cognizant (CTSH) reported health sciences — foreign currency translation adjustments of $5M in Q4 2025.
- How has Cognizant's health sciences — foreign currency translation adjustments changed year-over-year?
- Cognizant's health sciences — foreign currency translation adjustments increased by 253.8% year-over-year, from -$3.25M to $5M.
- What is the long-term trend for Cognizant's health sciences — foreign currency translation adjustments?
- Over 4 years (2021 to 2025), Cognizant's health sciences — foreign currency translation adjustments has grown at a 25.7% compound annual growth rate (CAGR), from -$8M to $20M.
- What does health sciences — foreign currency translation adjustments mean?
- This metric captures the impact of fluctuations in foreign exchange rates on the financial results of the Health Sciences segment, specifically regarding the translation of foreign subsidiary financial statements into the reporting currency. It reflects the volatility inherent in operating a global business with significant personnel and delivery centers outside the primary reporting jurisdiction. This adjustment is essential for isolating operational performance from currency-driven accounting noise.